Emerging Clinical Initiatives in Pharmaceutical Development:
Methodology and Regulatory Perspectives
- We would like to announce that a special issue based on the talks and the posters will be published on Journal of Biopharmaceutical Statistics (JBS). The special issue will be co-edited by Dr Herbert Pang (Genentech) and Dr Nelson Lu (FDA). They will soon follow up with more details about the process, but if you have any questions regarding to the special issue, please don’t hesitate to contact them.
The Duke-Industry Statistics Symposium (DISS) is organized by the Department of Biostatistics and Bioinformatics, Duke University School of Medicine and co-sponsored by Amgen, ASA-NC Chapter, Boehringer-Ingelheim, Genentech, ICSA, IQVIA, Janssen, Journal of Biopharmaceutical Statistics, Lilly, Merck, Otsuka, Parexel, PPD, SAS, UCB and ViiV. The symposium was established seven years ago to discuss challenging issues and recent advances related to the clinical development of drugs, biologics and devices and to promote research and collaboration among statisticians from industry, academia, and regulatory agencies.
|SAS||IQVIA||Eli Lilly and Company||Janssen|
|Otsuka||Journal of Biopharmaceutical Statistics||Intnat'l Chinese Statistical Association||ASA NC Chapter|